Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Matthew BohmRonghui XuYiran ZhangSashidhar VarmaMonika FischerGursimran KochharBrigid BolandSiddharth SinghRobert P HirtenRyan C UngaroEugenia ShmidtKaren LaschVipul JairaithDavid HudesmanShannon ChangDana LukinArun SwaminathBruce E SandsJean Frederic ColombelSunanda KaneEdward V LoftusBo ShenCorey A SiegelWilliam J SandbornParambir S Dulainull nullPublished in: Alimentary pharmacology & therapeutics (2020)
There was a lower risk of non-infectious serious adverse events, but not serious infections, with vedolizumab vs TNF-antagonist therapy, with no significant difference for achieving disease remission.